RT Journal Article
SR Electronic
T1 Safety and efficacy of Pulmonary physiotherapy in hospitalized patients with severe COVID-19 pneumonia (PPTCOVID Study): A prospective, randomised, single-blind, controlled trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.24.21255892
DO 10.1101/2021.04.24.21255892
A1 Javaherian, Mohammad
A1 Shadmehr, Azadeh
A1 Keshtkar, Abbasali
A1 Beigmohammadi, Mohammad-Taghi
A1 Dabbaghipour, Narges
A1 Syed, Aabis
A1 Moghadam, Behrouz Attarbashi
YR 2021
UL http://medrxiv.org/content/early/2021/08/02/2021.04.24.21255892.abstract
AB Background Pulmonary physiotherapy (PPT) is an important treatment in the management of patients with different types of pulmonary disorders. We aimed to evaluate safety and efficacy of PPT in hospitalized patients with severe COVID-19 pneumonia.Methods In this randomised, single-blind, controlled trial, we enrolled hospitalized, non-intubated patients (18 to 75 years with oxygen saturation (Spo2) in free-air breathing ≤90%) with COVID-19 pneumonia at a referral hospital. Participants were randomly assigned (1:1) to receive PPT (six sessions PPT with breathing exercises and airway clearance techniques) or basic care. The primary outcomes were venous blood O2 (pO2) and CO2 (pCO2) pressures, Spo2, and three-minute walking test (3MWT) that were assessed before and end of sixth session. Secondary outcomes included level of dyspnea, venous blood PH, one-month mortality, three-month mortality and short form-36 (SF-36) after one and three months. The assessor was blinded to the assignment. This trial is registered with ClinicalTrials.gov (NCT04357340).Findings In April-May 2020, 40 participants were randomly assigned to PPT or basic care groups. While at the end of intervention, pO2 (adjusted mean difference to baseline measure (AMD) 6.43 mmHg [95%CI 2.8, 10.07], P<0.01), Spo2 (AMD 4.43% [95%CI 2.04, 6.83], P=0.0011), and 3MTW (AMD 91.44 m [95%CI 68.88, 113.99], P<0.01) were higher in PPT group and basic care group, pCO2 was not improved (AMD -2.1 mmHg [95%CI-6.36, 2.21], P=0.33). Mortality rate was 20% (OR adjusted to baseline Spo2 .19 [95%CI .03, 1.30], P=.09) and 25% (OR adjusted to baseline Spo2 .16 [95%CI .26, 1.05], P=.056) lower in the PPT group at three-month at one-month and three-month, respectively. There were no significant differences in most SF-36 domains scores after one and three months. No serious adverse event was observed during PPT sessions.Conclusion Early PPT can be considered a safe and effective therapeutic choice for patients with severe COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04357340Funding StatementThis study was funded by the Tehran University of Medical Sciences. The founder of the study had no role in study design, data collection, analysis, interpretation, or writing the manuscript. The corresponding author had full access to all the data in the study and is responsible for publishing the results.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical Committee of Tehran University of Medical SciencesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll individual participant data that underline the results reported in this article, after de-identification (text, tables, figures, and appendices), study protocol, statistical analysis plan and Informed consent form are available from the corresponding author and Mohammad Javaherian (Email: Javaherian_m@razi.tums.ac.ir) for researchers who provide a related approved proposal and ethical committee approve to achieve aims. Patient-level information will be anonymised and study documents will be redacted to protect the privacy of trial patients. These data will be available with publication date until one year.